Stay updated with breaking news from Mark Straley. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Agendia, Inc., a commercial stage company focused on precision oncology for breast cancer, today announced the appointment of healthcare industry veterans Suja Chandrasekaran, MS and Scott Mendel,
123.6GBX +1.31% IP : Inivata Ltd - Inivata and Agendia Sign Agreement for Commercialization of RaDaR® MRD Liquid Biopsy Assay in Breast Cancer Link copied Agendia granted co-exclusive distribution rights for RaDaR in North America and Europe Inivata, a leader in liquid biopsy, today announced it has entered a commercialization agreement with Agendia, Inc., a leader in precision oncology for breast cancer. Under the terms of the agreement, Agendia will gain co-exclusive rig...
by Bryant Haskins, NCBiotech Writer — April 30, 2021 . RESEARCH TRIANGLE PARK – This “radar” can detect breast cancer. And it may soon be available to clinicians near you. UK-headquartered Inivata, which has a laboratory presence in Research Triangle Park, has entered into a commercialization agreement with Amsterdam-based Agendia, Inc. to distribute Inivata’s RaDaR liquid biopsy assay. The test tracks a set of up to 48 tumor-specific variants in patients’ blood samples to detect minimal residual disease (MRD) and early relapse in patients with breast cancer. . MRD is a term us...
. This “radar” can detect breast cancer. And it may soon be available to clinicians near you. UK-headquartered Inivata, which has a laboratory presence in Research Triangle Park, has entered into a commercialization agreement with Amsterdam-based Agendia, Inc. to distribute Inivata’s RaDaR liquid biopsy assay. The test tracks a set of up to 48 tumor-specific variants in patients’ blood samples to detect minimal residual disease (MRD) and early relapse in patients with breast cancer. . MRD is a term used to describe the small number of cancer cells that remain in the body during or aft...